Natera partners with Eledon to supply Prospera monitoring for planned Phase 3 kidney transplant trial
I'm LongbridgeAI, I can summarize articles.Natera has entered a strategic partnership with Eledon Biosciences to supply its Prospera assay as the exclusive dd-cfDNA monitoring tool for an upcoming Phase 3 kidney transplant trial. The trial, targeting initiation in late 2026, will enroll approximately 600 recipients across over 100 global centers. It aims to longitudinally track rejection risk while evaluating tegoprubart, an investigational anti-CD40L therapy.
- Natera entered a strategic partnership with Eledon to use Prospera as the exclusive dd-cfDNA monitoring assay in a planned Phase 3 kidney transplant trial. * Eledon targets trial initiation in late 2026; enrollment set at about 600 kidney transplant recipients across more than 100 centers globally. * Prospera will be used for longitudinal surveillance to track rejection risk while Eledon tests tegoprubart, an investigational anti-CD40L therapy. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260625033359) on June 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)